个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

CD25: A potential tumor therapeutic target

| 认领 | 导出 | |

文献详情

资源类型：
Pubmed体系：
作者：
Peng Yujia[1,2,3] ; Tao Yiran[1,2,3] ; Zhang Ya[1,4] ; Wang Jiaxing[5] ; Yang Jinliang[1] ; Wang Yuxi[1,3,*1] ;
机构： [1]State Key Laboratory of Biotherapy, Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, Frontiers Science Center for Disease- related Molecular Network, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, China. [2]West China-California Research Center for Predictive Intervention Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China. [3]Precision Medicine Key Laboratory of Sichuan Province & Precision Medicine Research Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China. [4]College of Life Sciences, Sichuan University, Chengdu, Sichuan, China. [5]Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
出处：
DOI： 10.1002/ijc.34281
ISSN：

关键词： anti-CD25 drugs CD25 regulatory T cells tumor immunotherapy

摘要：
CD25 is the alpha-chain of the heterotrimer IL-2 receptor. CD25 is expressed on the surface of both immune and non-immune cells with different frequencies. For cancers, CD25 is expressed at high levels in many types of hematological malignancies, but at low levels in most solid tumors. CD25 is also highly expressed in activated circulating immune cells and regulatory T cells (Tregs). Infiltration of Tregs in the tumor microenvironment can lead to an imbalanced ratio of effector T cells (Teffs) and Tregs, which is associated with the progression of cancers. A rescued Teff/Treg cell ratio indicates an efficient anti-tumor response to immunotherapy. CD25 as a potential target for the depletion of Tregs is critical in developing new immunotherapeutic strategies. Few articles have summarized the relationships between CD25 and tumors, or the recent progress of drugs targeting CD25. In this paper, we will discuss the structures of IL-2 and IL-2R, the biological function of CD25 and its important role in tumor therapy. In addition, the latest research on drugs targeting CD25 has been summarized, providing guidance for future drug development.© 2022 UICC.

基金：
National Major Scientific and Technological Special Project for ‘Significant New Drugs Development’, Grant/Award Number: 2018ZX09201018-021; National Natural Science Foundation of China, Grant/Award Number: 82073318; Sichuan Science and Technology Program, Grant/Award Number: 2019YFS0003
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类 | 1 区 医学
小类 | 2 区 肿瘤学
最新[2023]版：
大类 | 2 区 医学
小类 | 2 区 肿瘤学
第一作者：
第一作者机构： [1]State Key Laboratory of Biotherapy, Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, Frontiers Science Center for Disease- related Molecular Network, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, China. [2]West China-California Research Center for Predictive Intervention Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China. [3]Precision Medicine Key Laboratory of Sichuan Province & Precision Medicine Research Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
共同第一作者：
通讯作者：
通讯机构： [1]State Key Laboratory of Biotherapy, Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, Frontiers Science Center for Disease- related Molecular Network, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, China. [3]Precision Medicine Key Laboratory of Sichuan Province & Precision Medicine Research Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China. [*1]West China Hospital, Sichuan University, Chengdu, #37 Guoxue Alley, Wuhou District, Chengdu, Sichuan Province, 610041, China.
推荐引用方式(GB/T 7714)：
Peng Yujia,Tao Yiran,Zhang Ya,et al.CD25: A potential tumor therapeutic target[J].International journal of cancer.2022,doi:10.1002/ijc.34281.
APA：
Peng Yujia,Tao Yiran,Zhang Ya,Wang Jiaxing,Yang Jinliang&Wang Yuxi.(2022).CD25: A potential tumor therapeutic target.International journal of cancer,,
MLA：
Peng Yujia,et al."CD25: A potential tumor therapeutic target".International journal of cancer .(2022)

相关文献

[1] 骨转移瘤患者~（89）SrCl_2治疗前后外周血CD4~＋CD25~＋调节性T细胞及Foxp3 mRNA的表达变化 [2]间充质干细胞对去除CD4+CD25+调节性T细胞哮喘小鼠气道炎症的影响 [3]骨转移瘤患者89SrCl2治疗前后外周血CD4+ CD25+调节性T细胞及Foxp3mRNA的表达变化 [4]Dimethyl fumarate alleviates allergic asthma by strengthening the Nrf2 signaling pathway in regulatory T cells [5]Interleukin-35 in immune-related diseases: protection or destruction. [6]Normal human enthesis harbours conventional CD4+ and CD8+ T cells with regulatory features and inducible IL-17A and TNF expression. [7]Prognostic value of tumor-infiltrating Foxp3+regulatory T cells in patients with breast cancer: a meta-analysis [8]The immune regulatory effects of tetrahedral framework nucleic acid on human T cells via the mitogen-activated protein kinase pathway. [9]Tumor-infiltrating mast cells stimulate ICOS+ regulatory T cells through an IL-33 and IL-2 axis to promote gastric cancer progression [10]小鼠乳腺癌动物模型中调节性T细胞的 动态检测及其实验意义

资源点击量：43370 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号